$17.22 Million in Sales Expected for Seres Therapeutics Inc (MCRB) This Quarter

Wall Street analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to report $17.22 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Seres Therapeutics’ earnings. The highest sales estimate is $23.43 million and the lowest is $11.00 million. Seres Therapeutics reported sales of $23.02 million in the same quarter last year, which suggests a negative year over year growth rate of 25.2%. The firm is scheduled to report its next earnings report on Wednesday, November 14th.

According to Zacks, analysts expect that Seres Therapeutics will report full-year sales of $30.02 million for the current fiscal year, with estimates ranging from $24.60 million to $35.44 million. For the next financial year, analysts anticipate that the business will report sales of $21.02 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. The company had revenue of $4.61 million for the quarter, compared to analysts’ expectations of $5.22 million. Seres Therapeutics had a negative return on equity of 256.24% and a negative net margin of 264.31%.

Several brokerages recently issued reports on MCRB. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 4th. Bank of America cut Seres Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Friday, August 3rd. Zacks Investment Research raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 1st. Finally, BidaskClub cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 25th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $17.25.

In other Seres Therapeutics news, insider Roger Pomerantz sold 32,336 shares of the business’s stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $9.12, for a total value of $294,904.32. Following the transaction, the insider now owns 243,670 shares of the company’s stock, valued at $2,222,270.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP John G. Aunins sold 14,279 shares of the business’s stock in a transaction on Sunday, July 15th. The stock was sold at an average price of $8.10, for a total value of $115,659.90. Following the completion of the transaction, the executive vice president now directly owns 160,927 shares in the company, valued at approximately $1,303,508.70. The disclosure for this sale can be found here. In the last three months, insiders sold 189,287 shares of company stock worth $1,727,755. Insiders own 37.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Seres Therapeutics in the second quarter worth $117,000. Bank of America Corp DE boosted its position in Seres Therapeutics by 175.0% in the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock worth $314,000 after purchasing an additional 23,222 shares during the last quarter. A.R.T. Advisors LLC boosted its position in Seres Therapeutics by 141.3% in the first quarter. A.R.T. Advisors LLC now owns 45,952 shares of the biotechnology company’s stock worth $337,000 after purchasing an additional 26,909 shares during the last quarter. Chicago Equity Partners LLC purchased a new position in Seres Therapeutics in the second quarter worth $415,000. Finally, Alps Advisors Inc. boosted its position in Seres Therapeutics by 21.0% in the first quarter. Alps Advisors Inc. now owns 54,359 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 9,448 shares during the last quarter. 78.04% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:MCRB opened at $7.80 on Friday. The company has a market cap of $326.57 million, a P/E ratio of -3.53 and a beta of 0.54. The company has a debt-to-equity ratio of -0.61, a quick ratio of 2.76 and a current ratio of 2.76. Seres Therapeutics has a 12-month low of $6.65 and a 12-month high of $17.42.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Recommended Story: Outstanding Shares

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply